Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|
Aug. 14, 2019 |
Jun. 30, 2019 |
Mar. 31, 2019 |
Jun. 30, 2018 |
Mar. 31, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Jan. 02, 2019 |
Dec. 31, 2018 |
|
| Accumulated deficit | $ (9,344,044) | $ (9,344,044) | $ (7,624,134) | ||||||
| Net loss | (969,078) | $ (750,832) | $ (1,206,074) | $ (1,096,798) | (1,719,910) | $ (2,302,870) | |||
| Net cash used in operating activities | (1,018,976) | $ (2,233,186) | |||||||
| Cash and cash equivalents | 721,985 | 721,985 | 1,740,961 | ||||||
| Clinical Trial Funding commitment from investor capital | 1,400,000 | 1,400,000 | |||||||
| Payments made directly by investor for clinical trial costs | 280,927 | $ 115,000 | 395,927 | ||||||
| Impairment of long-lived assets | |||||||||
| Right-of-use asset | 256,916 | 256,916 | $ 293,198 | ||||||
| Lease obligations | $ 264,221 | $ 264,221 | $ 303,161 | ||||||
| Subsequent Event [Member] | 8% Senior Convertible Notes [Member] | |||||||||
| Proceeds from sale of debt | $ 435,000 | ||||||||
| Subsequent Event [Member] | Contract Research Organization [Member] | |||||||||
| Payments made directly by investor for clinical trial costs | $ 193,299 | ||||||||
| X | ||||||||||
- Definition Clinical trial funding commitment from investor capital. No definition available.
|
| X | ||||||||||
- Definition Payments made directly by investor for clinical trial costs. No definition available.
|
| X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Present value of lessee's discounted obligation for lease payments from operating lease. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of lessee's right to use underlying asset under operating lease. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|